Smith+Nephew gets FDA clearance for new hip surgery system

Smith+Nephew earned 501(k) clearance from the FDA for its Catalystem Primary Hip System.

Advertisement

The system aims to tackle the changing needs and demands of primary hip surgery, including the expanding role of ambulatory surgery centers in hip procedures, according to a July 16 news release. 

The Catalystem system is designed to be effective for direct anterior approach, which is becoming more common.

The direct anterior approach is a less invasive surgery, leading to improved range of motion and faster recovery times, the release said.

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Advertisement

Next Up in Orthopedic

Advertisement

Comments are closed.